Elicio Therapeutics, Inc. Increase (Decrease) in Contract with Customer, Liability
Elicio Therapeutics, Inc. (ELTX) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-13
- Elicio Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was $0.00.
- Elicio Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was $0.00.
- Elicio Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was $0.00.
- Elicio Therapeutics, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Elicio Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$1.17M, a 346.11% decline from fiscal 2024.
- Elicio Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $475.00K.
- Elicio Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$742.00K, a 151.67% decline from fiscal 2022.
- Elicio Therapeutics, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was $1.44M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 3 month as first filed | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 6 month as first filed | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 9 month as first filed | Increase (Decrease) in Contract with Customer, Liability 12 month | Increase (Decrease) in Contract with Customer, Liability 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $0.00 10-Q · filed 2026-05-11 | $0.00 derived: sum of 2 quarters · filed 2026-05-11 | $0.00 derived: sum of 3 quarters · filed 2026-05-11 | -$680.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | -$680.00K derived: sum of 3 quarters · filed 2026-08-13 | -$1.17M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$680.00K derived: sum of 2 quarters · filed 2026-08-13 | -$1.17M 10-Q · filed 2025-11-13 | -$1.31M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | -$680.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.17M 10-Q · filed 2026-08-13 | -$1.31M derived: sum of 3 quarters · filed 2026-08-13 | -$350.00K derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-03-31 | -$489.00K 10-Q · filed 2026-05-11 | -$627.00K derived: sum of 2 quarters · filed 2026-05-11 | $330.00K derived: sum of 3 quarters · filed 2026-05-11 | $53.00K derived: sum of 4 quarters · filed 2026-05-11 | ||||
| 2024-12-31 | -$138.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $819.00K derived: sum of 2 quarters · filed 2026-03-12 | $542.00K derived: sum of 3 quarters · filed 2026-03-12 | $475.00K 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $957.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $680.00K derived: sum of 2 quarters · filed 2025-11-13 | $613.00K 10-Q · filed 2025-11-13 | -$357.00K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$277.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$344.00K 10-Q · filed 2025-08-07 | -$1.31M derived: sum of 3 quarters · filed 2025-08-07 | $350.00K derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$67.00K 10-Q · filed 2025-05-13 | -$1.04M derived: sum of 2 quarters · filed 2025-05-13 | $627.00K derived: sum of 3 quarters · filed 2025-05-13 | -$302.00K derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$970.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $694.00K derived: sum of 2 quarters · filed 2025-03-31 | -$235.00K derived: sum of 3 quarters · filed 2025-03-31 | -$742.00K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $1.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $735.00K derived: sum of 2 quarters · filed 2024-11-13 | $228.00K 10-Q · filed 2024-11-13 | -$488.00K derived: sum of 4 quarters · filed 2024-11-13 | ||||
| 2023-06-30 | -$929.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$1.44M 10-Q · filed 2024-08-13 | -$2.15M derived: sum of 3 quarters · filed 2024-08-13 | $0.00 derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | -$507.00K 10-Q · filed 2024-05-15 | $0.00 10-Q · filed 2023-05-10 | -$1.22M derived: sum of 2 quarters · filed 2024-05-15 | $929.00K derived: sum of 3 quarters · filed 2024-05-15 | $2.58M derived: sum of 4 quarters · filed 2024-05-15 | |||
| 2022-12-31 | -$716.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $1.44M derived: sum of 2 quarters · filed 2024-03-29 | $3.08M derived: sum of 3 quarters · filed 2024-03-29 | $1.44M 10-K · filed 2024-03-29 | -$2.30M 10-K · filed 2023-03-17 | |||
| 2022-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $3.80M derived: sum of 2 quarters · filed 2023-11-13 | $2.15M 10-Q · filed 2023-11-13 | -$2.30M 10-Q · filed 2022-11-14 | -$22.98M derived: sum of 4 quarters · filed 2023-11-13 | |||
| 2022-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | -$2.30M 10-Q · filed 2022-08-15 | -$25.14M derived: sum of 3 quarters · filed 2023-08-14 | -$26.59M derived: sum of 4 quarters · filed 2023-08-14 | |||
| 2022-03-31 | -$1.65M 10-Q · filed 2023-05-10 | -$26.78M derived: sum of 2 quarters · filed 2023-05-10 | -$28.24M derived: sum of 3 quarters · filed 2023-05-10 | -$28.78M derived: sum of 4 quarters · filed 2023-05-10 | ||||
| 2021-12-31 | -$25.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | -$26.59M derived: sum of 2 quarters · filed 2023-03-17 | -$27.14M derived: sum of 3 quarters · filed 2023-03-17 | -$27.51M 10-K · filed 2023-03-17 | ||||
| 2021-09-30 | -$1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$2.00M derived: sum of 2 quarters · filed 2022-11-14 | -$2.37M 10-Q · filed 2022-11-14 | $27.44M derived: sum of 4 quarters · filed 2022-11-14 | ||||
| 2021-06-30 | -$541.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$912.00K 10-Q · filed 2022-08-15 | $28.89M derived: sum of 3 quarters · filed 2022-08-15 | $28.89M derived: sum of 4 quarters · filed 2022-08-15 | ||||
| 2021-03-31 | -$371.00K 10-Q · filed 2022-05-16 | $29.44M derived: sum of 2 quarters · filed 2022-05-16 | $29.44M derived: sum of 3 quarters · filed 2022-05-16 | $29.44M derived: sum of 4 quarters · filed 2022-05-16 | ||||
| 2020-12-31 | $29.81M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $29.81M derived: sum of 2 quarters · filed 2022-03-30 | $29.81M derived: sum of 3 quarters · filed 2022-03-30 | $29.81M 10-K · filed 2022-03-30 | ||||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |